P Tech v. Arthrex: Federal Circuit Affirms Unpatentability of Fixation Systems Patent
P Tech, LLC appealed an invalidity ruling against US10881440B2, covering fixation systems and methods used in orthopedic surgery. The Federal Circuit affirmed per curiam, leaving Arthrex, Inc. free of the patent challenge. The appeal closed after 572 days, with all three judges concurring without written opinion.
Federal Circuit affirms cancellation of P Tech’s orthopedic fixation patent
P Tech, LLC brought Case No. 24-1265 before the United States Court of Appeals for the Federal Circuit, appealing an adverse patentability determination against US10881440B2 — a patent directed to fixation systems and methods in the orthopedic surgery domain. The appeal was filed on December 15, 2023, with Arthrex, Inc., a major orthopedic device manufacturer, as the prevailing respondent. P Tech was represented by Lewis Rice LLC, with counsel including Robert M. Evans and Michael J. Hartley, while Arthrex retained Venable LLP with Justin J. Oliver and Megan S. Woodworth.
The Federal Circuit issued a per curiam affirmance on July 9, 2025, pursuant to Federal Circuit Rule 36 — a summary disposition indicating that the panel found no reversible error warranting a written opinion. Chief Judge Moore, Judge Prost, and Judge Reyna concurred. The basis of termination is recorded as ‘Unpatentable,’ confirming that the underlying invalidity or cancellation action against US10881440B2 succeeded, and the patent cannot be enforced. P Tech exhausted its appellate options at this court level.
The 572-day duration from filing to decision is broadly consistent with Federal Circuit appeal timelines in patent validity disputes. The Rule 36 affirmance, while legally conclusive, offers limited public insight into the specific prior art or legal theories that drove the outcome. What remains unknown from the public record is the precise basis of unpatentability — whether obviousness, anticipation, or another statutory ground — as the per curiam disposition forecloses detailed analysis of the panel’s reasoning.
Filing to Unpatentable in 572 days
572 days from filing to Federal Circuit decision — consistent with typical inter partes appeal timelines
Federal Circuit affirms: what the ruling means for both parties
Rule 36 affirmance: the court found no reversible error below
A Federal Circuit Rule 36 affirmance means the panel unanimously agreed the decision below was correct but declined to issue a written opinion. This is a legally binding and final disposition — it affirms the lower tribunal’s finding that US10881440B2 is unpatentable. It does not establish new precedent, but it conclusively ends P Tech’s ability to revive this patent through further appeals at this court level.
Per curiam, no written opinionUS10881440B2 is cancelled — P Tech loses enforcement rights
For P Tech, LLC, the affirmance is a definitive adverse outcome. US10881440B2 — covering fixation systems and methods — is confirmed unpatentable, stripping P Tech of any enforcement, licensing, or royalty leverage derived from this patent. The path to the Supreme Court remains theoretically open via certiorari, but Federal Circuit Rule 36 affirmances rarely attract high court review, particularly absent a circuit split or significant legal question.
Patent cancelled, no enforcement rightsArthrex secures freedom to operate in fixation technology
Arthrex, Inc. emerges from this appeal with the unpatentability finding firmly upheld. The company’s fixation systems and methods product lines are no longer exposed to infringement claims under US10881440B2. This outcome also raises the bar for any future patent assertion by P Tech or related entities over substantially similar claim scope, as the cancelled patent cannot be revived at this appellate level.
Freedom to operate confirmedAffirmance strengthens Arthrex’s competitive position in orthopedic fixation
The Federal Circuit’s affirmance signals that the claims of US10881440B2 could not withstand patentability scrutiny, which may encourage competitors and IPR petitioners to scrutinise related P Tech patents covering similar orthopedic fixation technology. For Arthrex and similarly situated device makers, the ruling reduces litigation risk and may influence licensing negotiations across the fixation systems segment of the orthopedic surgical market.
Reduced litigation risk for sectorFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | P Tech, LLC | Company | Orthopedic technology patent holding entity — holder of US10881440B2Search in Eureka ↗ |
| Defendant | Arthrex, Inc. | Company | Arthrex, Inc. — global orthopedic surgical device manufacturer and distributorSearch in Eureka ↗ |
| Plaintiff counsel | Kathleen Markowski Petrillo | Attorney | Counsel for P Tech, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Michael Henry Durbin | Attorney | Counsel for P Tech, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Michael J. Hartley | Attorney | Counsel for P Tech, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Robert M. Evans | Attorney | Counsel for P Tech, LLCSearch in Eureka ↗ |
| Plaintiff law firm | Lewis Rice LLC | Law Firm | Representing P Tech, LLCSearch in Eureka ↗ |
| Defendant counsel | Justin J. Oliver | Attorney | Counsel for Arthrex, Inc.Search in Eureka ↗ |
| Defendant counsel | Megan S. Woodworth | Attorney | Counsel for Arthrex, Inc.Search in Eureka ↗ |
| Defendant law firm | Venable LLP | Law Firm | Representing Arthrex, Inc.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | Court of Appeals for the Federal CircuitSearch in Eureka ↗ |
Official order — verbatim text
The per curiam disposition — ‘AFFIRMED. See Fed. Cir. R. 36.’ — is the Federal Circuit’s most summary form of affirmance, issued without a written opinion when the panel unanimously finds no reversible error in the lower tribunal’s patentability determination. Under the appellate standard of review, legal conclusions on patentability are reviewed de novo and factual findings for substantial evidence. The Rule 36 affirmance signals the panel found the record sufficient to sustain the unpatentability finding on both fronts, leaving US10881440B2 conclusively cancelled with no further recourse at this court level for P Tech.
US10881440B2 — Fixation Systems and Methods (Orthopedic Surgery)
US10881440B2, filed under application number US16/133420, is directed to fixation systems and methods — technology relevant to surgical anchoring and stabilisation in orthopedic procedures. The patent covers methods and apparatus for securing tissue, bone, or implants in surgical contexts. Its grant reflects a claim scope that was ultimately found unsupportable under patentability review, suggesting the claims may have relied on prior art approaches that were insufficiently distinguished at the prosecution stage or in inter partes proceedings.
In the orthopedic surgical device sector, fixation technology patents are competitively significant — companies like Arthrex, Stryker, Smith & Nephew, and Zimmer Biomet operate in closely contested IP landscapes where patent portfolios directly influence market access and licensing dynamics. The cancellation of US10881440B2 removes one assertion vector that P Tech held against device makers in this space. However, patent holding entities in this sector typically maintain broader portfolios, meaning the strategic risk from related continuations or sibling patents may persist for Arthrex and competitors.
Should you run an FTO against US10881440B2?
For R&D and product teams developing fixation systems, surgical anchoring devices, or related orthopedic implant technologies, US10881440B2 has been confirmed unpatentable and cannot be enforced. However, freedom-to-operate analysis should extend beyond this single cancelled patent to the broader P Tech portfolio. Related continuation applications or co-pending patents with overlapping claim scope may still present infringement risk, particularly for companies operating in suture anchors, bone fixation, or tissue repair product categories.
PatSnap Eureka’s FTO Search Agent enables R&D teams to map their product features against the full P Tech patent family — including active siblings of US10881440B2 — in minutes rather than weeks. Eureka identifies claim overlap, flags live enforcement risk from related patents, and surfaces prior art that supports design-around or invalidity arguments. For orthopedic device teams, running a structured FTO before product launch or licensing negotiation is essential given the density of patent assertion activity in this sector.
Run a freedom-to-operate analysis on US10881440B2 to assess your product’s exposure
Run FTO in Eureka →Similar Federal Circuit appeals: orthopedic fixation patent validity disputes
Federal Circuit appeals involving orthopedic fixation and surgical device patents affirmed or reversed on patentability grounds — comparable to P Tech v. Arthrex, Case No. 24-1265.
What this case signals for the orthopedic device IP landscape
A Rule 36 affirmance of unpatentability at the Federal Circuit sends a clear signal to patent holders and challengers in orthopedic surgical technology.
Rule 36 affirmances carry full legal weight despite lacking written reasoning
IP professionals should note that Federal Circuit Rule 36 dispositions are binding and final at that court level. Competitors and licensees facing similar patents can treat the unpatentability finding as commercially conclusive for US10881440B2. The absence of a written opinion limits precedential value but does not diminish the practical effect on enforcement rights.
Related P Tech patents in orthopedic fixation may now face heightened IPR scrutiny
Affirmance of unpatentability on one patent within a portfolio typically invites broader prior art analysis of sibling or continuation patents. Companies operating in fixation systems and methods — particularly those facing P Tech assertions — should audit the P Tech portfolio for claims with similar scope and evaluate IPR petition strategies accordingly.
P v Arthrex — key questions answered
The Federal Circuit affirmed the unpatentability of US10881440B2 in a per curiam Rule 36 disposition. Chief Judge Moore, Judge Prost, and Judge Reyna unanimously affirmed the lower tribunal’s finding without issuing a written opinion. The patent, covering fixation systems and methods, is cancelled and unenforceable.
A Rule 36 affirmance means the Federal Circuit panel found no reversible error in the lower decision but declined to write an opinion explaining its reasoning. For US10881440B2, this is a final, binding determination of unpatentability. P Tech retains the theoretical option of seeking Supreme Court certiorari, but such petitions are rarely granted in patent validity cases absent a circuit split.
US10881440B2 is directed to fixation systems and methods — technology relevant to surgical anchoring in orthopedic procedures. Arthrex is a major manufacturer of orthopedic surgical devices including fixation products. Cancellation of this patent removes P Tech’s ability to assert infringement claims against Arthrex’s fixation product lines, improving Arthrex’s freedom to operate in this technology area.
Federal Circuit Rule 36 permits a summary affirmance without opinion when the panel unanimously agrees that the lower tribunal’s decision is correct and that no new legal question requires published analysis. This mechanism is commonly used in patent validity appeals where the factual record is sufficient to resolve the case. The absence of a written opinion does not diminish the legal finality of the outcome.
For orthopedic device companies, the affirmance confirms that US10881440B2 presents no ongoing enforcement risk. However, companies should conduct FTO analysis against the broader P Tech patent portfolio, as related continuation patents covering similar fixation claim scope may remain active. The ruling also suggests that IPR challenges to P Tech’s patents can be effective, which may inform litigation strategy for other defendants facing assertions from P Tech or similar NPEs.
PatSnap Eureka searches patents and litigation data to answer instantly.